eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate ...
eFFECTOR Therapeutics (NASDAQ:EFTR) jumped ~117% in the pre-market Friday after Stifel upgraded the nano-cap biotech citing interim Phase 2 data for the company's investigational therapy zotatifin as ...
In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that coronavirus disease 2019 (COVID-19) convalescent plasmas (CCPs) with low neutralizing and high fragment ...
Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ:LWAC) with an enterprise value of ...
A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal. A PIPE of $60 million is part of the SPAC merger and includes an investment ...
Hussein Gharakhani and Xin Zhang, both assistant professors in Mississippi State’s Department of Agricultural and Biological Engineering, are working to develop a robot that can harvest cotton. (Photo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results